Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
@article{ATM39887,
author = {Mary E. Westerman and Christopher G. Wood},
title = {Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study},
journal = {Annals of Translational Medicine},
volume = {8},
number = {16},
year = {2020},
keywords = {},
abstract = {},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/39887}
}